Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 18.9% in March
by Renee Jackson · The Cerbat GemJyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 234,254 shares, a drop of 18.9% from the March 15th total of 288,865 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average daily volume of 201,892 shares, the days-to-cover ratio is currently 1.2 days.
Jyong Biotech Stock Performance
Shares of NASDAQ:MENS traded down $0.15 during midday trading on Friday, hitting $2.44. 194,919 shares of the company’s stock traded hands, compared to its average volume of 139,480. The firm’s fifty day moving average price is $2.16 and its two-hundred day moving average price is $17.53. Jyong Biotech has a twelve month low of $1.43 and a twelve month high of $67.00.
Jyong Biotech (NASDAQ:MENS – Get Free Report) last posted its earnings results on Friday, January 9th. The company reported ($0.01) earnings per share for the quarter.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Jyong Biotech has a consensus rating of “Sell”.
Check Out Our Latest Research Report on MENS
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech in the 4th quarter worth about $49,000. Man Group plc bought a new stake in shares of Jyong Biotech during the 4th quarter valued at about $56,000. BNP Paribas Financial Markets bought a new stake in shares of Jyong Biotech during the 3rd quarter valued at about $67,000. Millennium Management LLC grew its position in shares of Jyong Biotech by 209.4% during the 4th quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock valued at $159,000 after buying an additional 27,245 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock valued at $254,000 after buying an additional 10,538 shares during the last quarter.
Jyong Biotech Company Profile
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.